Atrium Therapeutics, Inc.
RNA
$13.19
$0.413.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Net Income | -16.63M | -29.14M | -7.45M | ||
| Total Depreciation and Amortization | 151.00K | 122.00K | 53.00K | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | 13.05M | 4.00M | 1.27M | ||
| Change in Net Operating Assets | -27.72M | 5.76M | -4.97M | ||
| Cash from Operations | -31.14M | -19.25M | -11.10M | ||
| Capital Expenditure | -2.10M | -879.00K | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -2.10M | -879.00K | -- | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | 301.51M | 20.13M | 11.10M | ||
| Cash from Financing | 301.51M | 20.13M | 11.10M | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 268.26M | -- | -- | ||